Free Trial

India Capital Growth (IGC) Competitors

India Capital Growth logo
GBX 168.68 -0.32 (-0.19%)
As of 03:37 AM Eastern

IGC vs. SLN, AMYT, BMY, OGN, GPH, ARTL, PHAR, AURA, KOD, and ORPH

Should you be buying India Capital Growth stock or one of its competitors? The main competitors of India Capital Growth include Silence Therapeutics (SLN), Amryt Pharma (AMYT), Bloomsbury Publishing (BMY), Origin Enterprises (OGN), Global Ports (GPH), Alpha Real Trust (ARTL), Pharos Energy (PHAR), Aura Energy (AURA), Kodal Minerals (KOD), and Open Orphan (ORPH). These companies are all part of the "pharmaceutical products" industry.

India Capital Growth vs.

India Capital Growth (LON:IGC) and Silence Therapeutics (LON:SLN) are both small-cap financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.

In the previous week, India Capital Growth had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for India Capital Growth and 0 mentions for Silence Therapeutics. India Capital Growth's average media sentiment score of 0.82 beat Silence Therapeutics' score of 0.00 indicating that India Capital Growth is being referred to more favorably in the media.

Company Overall Sentiment
India Capital Growth Positive
Silence Therapeutics Neutral

India Capital Growth has a net margin of 93.35% compared to Silence Therapeutics' net margin of 0.00%. India Capital Growth's return on equity of 25.12% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
India Capital Growth93.35% 25.12% 15.98%
Silence Therapeutics N/A N/A N/A

24.3% of India Capital Growth shares are owned by institutional investors. 0.2% of India Capital Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

India Capital Growth has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than India Capital Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
India Capital Growth£46.21M3.15£43.14M£49.523.41
Silence Therapeutics£11.35M0.00N/A-£48.60N/A

Silence Therapeutics received 185 more outperform votes than India Capital Growth when rated by MarketBeat users. Likewise, 68.81% of users gave Silence Therapeutics an outperform vote while only 56.25% of users gave India Capital Growth an outperform vote.

CompanyUnderperformOutperform
India Capital GrowthOutperform Votes
18
56.25%
Underperform Votes
14
43.75%
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%

Summary

India Capital Growth beats Silence Therapeutics on 10 of the 12 factors compared between the two stocks.

Get India Capital Growth News Delivered to You Automatically

Sign up to receive the latest news and ratings for IGC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IGC vs. The Competition

MetricIndia Capital GrowthAsset Management IndustryFinancial SectorLON Exchange
Market Cap£145.64M£1.14B£3.85B£2.56B
Dividend YieldN/A4.46%4.21%4.84%
P/E Ratio3.4121.7713.05132.40
Price / Sales3.152,283.531,689.09240,284.87
Price / Cash97.3161.4750.4928.16
Price / Book0.851.143.414.55
Net Income£43.14M£263.56M£1.25B£5.85B
7 Day Performance1.01%1.18%1.07%2.57%
1 Month Performance5.42%10.63%13.01%8.70%
1 Year Performance-5.24%2.37%12.78%113.17%

India Capital Growth Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IGC
India Capital Growth
N/AGBX 168.68
-0.2%
N/A-4.2%£145.64M£46.21M3.4161
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
BMY
Bloomsbury Publishing
2.4943 of 5 stars
GBX 557
-3.0%
GBX 825
+48.1%
+10.9%£449.46M£382.40M11.9234,300
OGN
Origin Enterprises
N/AGBX 3
-3.2%
N/A+6.1%£316.76M£183.08B8.6710,000Dividend Increase
GPH
Global Ports
N/AN/AN/AN/A£231.21M£193.58M30,000.0020
ARTL
Alpha Real Trust
N/AN/AN/AN/A£113.12M£8.46M96.445Gap Up
High Trading Volume
PHAR
Pharos Energy
N/AGBX 19.25
+7.5%
N/A-20.2%£96.03M£196.07M-2.05280News Coverage
Gap Up
AURA
Aura Energy
N/AGBX 5
-4.8%
N/A-32.5%£89.87MN/A-10,960.1150News Coverage
Gap Down
KOD
Kodal Minerals
1.9342 of 5 stars
GBX 0.38
-1.3%
GBX 1.23
+222.4%
-26.1%£76.63MN/A2,920.8390
ORPH
Open Orphan
N/AN/AN/AN/A£67.09M£34.71M-25.30179

Related Companies and Tools


This page (LON:IGC) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners